FOLD logo

Amicus Therapeutics (FOLD) Cash From Financing

Annual CFF

$61.68 M
+$69.14 M+926.44%

December 31, 2023

Summary

Performance

1-Year Change

+926.44%

3-Year Change

-76.54%

5-Year Change

-86.32%

15-Year Change

-75.07%

FOLD Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

80.51%
FOLD annual cash flow from financing activities is higher than 80.51% of companies in Healthcare sector

High & Low

All-time High

$450.77 M
FOLD annual cash flow from financing activities is currently -86.32% below its historical high of $450.77 million

3-Year Low

-$7.46 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
FOLD previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 28, 2025
FOLD next annual earnings announcement is scheduled for Feb 28, 2025

OtherFOLDcash flowmetrics:

Annual CFI

$98.06 M
FOLD annual cash flow from investing activities is $98.06 million

Annual CFO

-$69.09 M
FOLD annual cash flow from operations is -$69.09 million

Annual FCF

-$76.53 M
FOLD annual free cash flow is -$76.53 million

Annual CAPEX

$7.44 M
FOLD annual capital expenditures is $7.44 million

Quarterly CFF

$18.19 M
+$19.05 M+2222.52%

September 30, 2024

Summary

Performance

3-Month Change

+2222.52%

1-Year Change

-51.65%

3-Year Change

-51.65%

5-Year Change

-51.65%

FOLD Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

89.49%
FOLD quarterly cash flow from financing activities is higher than 89.49% of companies in Healthcare sector

High & Low

All-time High

$296.58 M
FOLD quarterly cash flow from financing activities is currently -93.87% below its historical high of $296.58 million

3-Year Low

-$13.31 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
FOLD previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
FOLD next earnings announcement is scheduled for Feb 28, 2025

OtherFOLDcash flowmetrics:

Quarterly CFI

$34.27 M
FOLD quarterly cash flow from investing activities is $34.27 million

Quarterly CFO

-$22.97 M
FOLD quarterly cash flow from operations is -$22.97 million

Quarterly FCF

-$23.33 M
FOLD quarterly free cash flow is -$23.33 million

Quarterly CAPEX

$356.00 K
FOLD quarterly capital expenditures is $356.00 thousand

TTM CFF

$12.23 M
-$19.43 M-61.36%

September 30, 2024

Summary

Performance

3-Month Change

-61.36%

1-Year Change

-77.35%

3-Year Change

-77.35%

5-Year Change

-77.35%

FOLD TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

57.53%
FOLD TTM cash flow from financing activities is higher than 57.53% of companies in Healthcare sector

High & Low

All-time High

$560.66 M
FOLD TTM cash flow from financing activities is currently -97.82% below its historical high of $560.66 million

3-Year Low

-$8.12 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
FOLD previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
FOLD next earnings announcement is scheduled for Feb 28, 2025

OtherFOLDcash flowmetrics:

TTM CFI

-$4.13 M
FOLD TTM cash flow from investing activities is -$4.13 million

TTM CFO

-$26.52 M
FOLD TTM cash flow from operations is -$26.52 million

TTM FCF

-$31.51 M
FOLD TTM free cash flow is -$31.51 million

TTM CAPEX

$5.00 M
FOLD TTM capital expenditures is $5.00 million

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

FOLD Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+926.4%-51.6%-77.3%
3 y3 years-76.5%-51.6%-77.3%
5 y5 years-86.3%-51.6%-77.3%

FOLD Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-70.9%+926.4%-51.6%+236.7%-94.2%+250.6%
5 y5-year-76.5%+926.4%-92.4%+236.7%-95.5%+250.6%
alltimeall time-86.3%+926.4%-93.9%+236.7%-97.8%+250.6%

Amicus Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
$18.19 M(-2222.5%)
$12.23 M(-61.4%)
Jun 2024
-
-$857.00 K(-93.6%)
$31.66 M(-43.7%)
Mar 2024
-
-$13.31 M(-262.1%)
$56.19 M(-8.9%)
Dec 2023
$61.68 M(-926.4%)
$8.21 M(-78.2%)
$61.68 M(+14.2%)
Sep 2023
-
$37.62 M(+58.9%)
$54.02 M(+240.9%)
Jun 2023
-
$23.67 M(-402.5%)
$15.85 M(-322.1%)
Mar 2023
-
-$7.83 M(-1504.8%)
-$7.13 M(-4.4%)
Dec 2022
-$7.46 M(-103.5%)
$557.00 K(-199.6%)
-$7.46 M(-8.1%)
Sep 2022
-
-$559.00 K(-180.7%)
-$8.12 M(-104.2%)
Jun 2022
-
$693.00 K(-108.5%)
$193.55 M(-0.8%)
Mar 2022
-
-$8.15 M(+7740.4%)
$195.09 M(-8.0%)
Dec 2021
$212.07 M(-19.3%)
-$104.00 K(-100.1%)
$212.07 M(-9.3%)
Sep 2021
-
$201.11 M(+8898.3%)
$233.72 M(-13.9%)
Jun 2021
-
$2.23 M(-74.7%)
$271.32 M(-0.7%)
Mar 2021
-
$8.83 M(-59.0%)
$273.17 M(+3.9%)
Dec 2020
$262.86 M(+20.9%)
$21.55 M(-91.0%)
$262.86 M(+7.5%)
Sep 2020
-
$238.71 M(+5742.2%)
$244.50 M(+3773.0%)
Jun 2020
-
$4.09 M(-374.8%)
$6.31 M(-96.8%)
Mar 2020
-
-$1.49 M(-146.6%)
$198.63 M(-8.7%)
Dec 2019
$217.50 M(-51.7%)
$3.19 M(+510.1%)
$217.50 M(+1.3%)
Sep 2019
-
$523.00 K(-99.7%)
$214.67 M(-40.5%)
Jun 2019
-
$196.40 M(+1029.8%)
$360.95 M(+110.4%)
Mar 2019
-
$17.38 M(+4742.3%)
$171.58 M(-61.9%)
Dec 2018
$450.77 M(+82.2%)
$359.00 K(-99.8%)
$450.77 M(-1.4%)
Sep 2018
-
$146.80 M(+1987.4%)
$457.28 M(-18.4%)
Jun 2018
-
$7.03 M(-97.6%)
$560.66 M(+3.0%)
Mar 2018
-
$296.58 M(+4220.8%)
$544.11 M(+119.9%)
Dec 2017
$247.43 M(-9.3%)
$6.86 M(-97.3%)
$247.43 M(-36.7%)
Sep 2017
-
$250.19 M(-2726.9%)
$390.89 M(+116.8%)
Jun 2017
-
-$9.52 M(>+9900.0%)
$180.34 M(-34.0%)
Mar 2017
-
-$95.00 K(-100.1%)
$273.12 M(+0.1%)
Dec 2016
$272.71 M(-6.2%)
$150.32 M(+279.3%)
$272.71 M(+122.5%)
Sep 2016
-
$39.63 M(-52.4%)
$122.55 M(-10.2%)
Jun 2016
-
$83.26 M(<-9900.0%)
$136.41 M(-52.4%)
Mar 2016
-
-$502.00 K(-432.5%)
$286.33 M(-1.6%)
Dec 2015
$290.89 M
$151.00 K(-99.7%)
$290.89 M(-25.3%)
DateAnnualQuarterlyTTM
Sep 2015
-
$53.50 M(-77.1%)
$389.39 M(+8.7%)
Jun 2015
-
$233.18 M(+5639.0%)
$358.25 M(+150.0%)
Mar 2015
-
$4.06 M(-95.9%)
$143.33 M(+3.0%)
Dec 2014
$139.18 M(+373.7%)
$98.64 M(+341.1%)
$139.18 M(+98.2%)
Sep 2014
-
$22.36 M(+22.5%)
$70.21 M(+47.0%)
Jun 2014
-
$18.25 M(<-9900.0%)
$47.75 M(+62.4%)
Mar 2014
-
-$85.00 K(-100.3%)
$29.39 M(+0.1%)
Dec 2013
$29.38 M(-63.9%)
$29.68 M(<-9900.0%)
$29.38 M(>+9900.0%)
Sep 2013
-
-$100.00 K(+1.0%)
$162.00 K(-99.1%)
Jun 2013
-
-$99.00 K(-1.0%)
$18.11 M(+1.8%)
Mar 2013
-
-$100.00 K(-121.7%)
$17.80 M(-78.2%)
Dec 2012
$81.48 M(-8823.6%)
$461.00 K(-97.4%)
$81.48 M(+1.0%)
Sep 2012
-
$17.85 M(-4391.1%)
$80.70 M(+29.0%)
Jun 2012
-
-$416.00 K(-100.7%)
$62.55 M(-0.7%)
Mar 2012
-
$63.58 M(<-9900.0%)
$62.97 M(-6842.1%)
Dec 2011
-$934.00 K(-102.1%)
-$313.00 K(+3.3%)
-$934.00 K(-103.4%)
Sep 2011
-
-$303.00 K(-6160.0%)
$27.11 M(+0.3%)
Jun 2011
-
$5000.00(-101.5%)
$27.04 M(+1.7%)
Mar 2011
-
-$323.00 K(-101.2%)
$26.59 M(-39.1%)
Dec 2010
$43.66 M(+1476.7%)
$27.73 M(-7553.5%)
$43.66 M(+179.8%)
Sep 2010
-
-$372.00 K(-16.6%)
$15.60 M(-6.2%)
Jun 2010
-
-$446.00 K(-102.7%)
$16.63 M(-15.9%)
Mar 2010
-
$16.75 M(-5222.0%)
$19.78 M(+614.3%)
Dec 2009
$2.77 M(-377.5%)
-$327.00 K(-149.8%)
$2.77 M(-1.2%)
Sep 2009
-
$657.00 K(-75.7%)
$2.80 M(+45.3%)
Jun 2009
-
$2.70 M(-1130.9%)
$1.93 M(-271.1%)
Mar 2009
-
-$262.00 K(-10.9%)
-$1.13 M(+12.9%)
Dec 2008
-$998.00 K(-101.1%)
-$294.00 K(+35.5%)
-$998.00 K(+0.3%)
Sep 2008
-
-$217.00 K(-38.7%)
-$995.00 K(-3.4%)
Jun 2008
-
-$354.00 K(+166.2%)
-$1.03 M(-101.5%)
Mar 2008
-
-$133.00 K(-54.3%)
$67.83 M(-26.2%)
Dec 2007
$91.91 M(+38.9%)
-$291.00 K(+15.5%)
$91.91 M(-0.3%)
Sep 2007
-
-$252.00 K(-100.4%)
$92.20 M(-0.3%)
Jun 2007
-
$68.51 M(+186.1%)
$92.45 M(+286.1%)
Mar 2007
-
$23.95 M
$23.95 M
Dec 2006
$66.17 M(+60.4%)
-
-
Dec 2005
$41.25 M
-
-

FAQ

  • What is Amicus Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for Amicus Therapeutics?
  • What is Amicus Therapeutics annual CFF year-on-year change?
  • What is Amicus Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Amicus Therapeutics?
  • What is Amicus Therapeutics quarterly CFF year-on-year change?
  • What is Amicus Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Amicus Therapeutics?
  • What is Amicus Therapeutics TTM CFF year-on-year change?

What is Amicus Therapeutics annual cash flow from financing activities?

The current annual CFF of FOLD is $61.68 M

What is the all time high annual CFF for Amicus Therapeutics?

Amicus Therapeutics all-time high annual cash flow from financing activities is $450.77 M

What is Amicus Therapeutics annual CFF year-on-year change?

Over the past year, FOLD annual cash flow from financing activities has changed by +$69.14 M (+926.44%)

What is Amicus Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of FOLD is $18.19 M

What is the all time high quarterly CFF for Amicus Therapeutics?

Amicus Therapeutics all-time high quarterly cash flow from financing activities is $296.58 M

What is Amicus Therapeutics quarterly CFF year-on-year change?

Over the past year, FOLD quarterly cash flow from financing activities has changed by -$19.43 M (-51.65%)

What is Amicus Therapeutics TTM cash flow from financing activities?

The current TTM CFF of FOLD is $12.23 M

What is the all time high TTM CFF for Amicus Therapeutics?

Amicus Therapeutics all-time high TTM cash flow from financing activities is $560.66 M

What is Amicus Therapeutics TTM CFF year-on-year change?

Over the past year, FOLD TTM cash flow from financing activities has changed by -$41.79 M (-77.35%)